Associate Professor, Hematology and Medical Oncology
Emory School of Medicine
Phase I Clinical Trials Unit
Dr. Harvey obtained his BS Pharmacy and Doctor of Pharmacy degrees at the University of North Carolina at Chapel Hill (UNC). He completed subsequent training at the University of Kentucky Medical Center and School of Pharmacy and specialized in Hematology/Oncology at UNC, where he served on staff and faculty for 8 years prior to coming to Grady Hospital in Atlanta. Since joining Emory, he has led the Phase I Clinical Trials Section in shepherding first-in-human compounds, investigator-initiated studies, and cooperative group trials in patients with refractory solid tumor and hematologic malignancies.
The application of clinical pharmacology principles to improved treatment outcomes is the driver of Dr. Harvey’s research. A complete understanding of drug disposition through population and individualized pharmacokinetic (PK) parameters leads to better treatment tailoring of novel and existing antineoplastics, and Dr. Harvey’s group is actively pursuing this application. Investigations of surrogate endpoints of drug response and target inhibition [pharmacodynamics (PD)] in peripheral and tumor tissues are also incorporated into a more complete understanding of drug action in his team’s clinical trials. Dr. Harvey’s goal is to combine PK, PD, and pharmacogenomics (PG) data in order to provide a comprehensive understanding of the variables involved in drug disposition, leading to optimization of anticancer therapies.
View publications on PubMed